Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

PrEP news

Show

From To
PrEP: So Effective, It's Unheard Of

As gay, bisexual and queer men and transgender individuals get more familiar with the drug, new possibilities continue to open up for us. Even so, the general heterosexual community has shown little excitement over this breakthrough -- even a widespread ignorance to the treatment's very existence.

Published
27 February 2015
From
The Body.com
UNAIDS welcomes further evidence of the efficacy of antiretroviral medicines in preventing new HIV infections

UNAIDS strongly welcomes results from scientific trials presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI), held in Seattle, United States of America.

Published
27 February 2015
From
UNAIDS
HIV pill: The logic of paying £500 a month so gay men don't have to wear condoms

At a time when the NHS is under immense financial strain – some might say bankrupt – it may seem odd to suggest that the health service pay nearly £500 a month for a gay man to take a daily pill so that he doesn’t have to wear a condom. However, the scientists behind this clinical trial believe that a policy of offering daily drugs aimed at curbing new HIV infections within certain high-risk groups of men who have sex with men may actually save the NHS money in the long term.

Published
26 February 2015
From
The Independent
Sexual Transmission of HCV in Gay Men Should Not Be a PrEP Deterrent, Say Advocates

After two men on pre-exposure prophylaxis (PrEP) at the Kaiser Permanente San Francisco Medical Center tested positive for the hepatitis C virus (HCV), clinicians at the center penned a letter to the editor of the journal Clinical Infectious Diseases calling for routine HCV testing in gay men who are currently on PrEP. The two men were among 485 HIV-negative gay men receiving PrEP at the clinic between 2011 and 2014.

Published
26 February 2015
From
The Body
What We Know About HIV Transmission Should Influence PrEP Messaging

It is pretty clear that those who are diagnosed with HIV who are in care and on medicine are not spreading the virus. So why do people continue to discuss PrEP solely in the context of having known HIV-positive partners? And in what ways do we still stigmatize people living with HIV in our discussions around PrEP as a tool to bridge the viral divide?

Published
26 February 2015
From
The Body
HIV treatment finally has a game-changer, and it’s called Truvada

The widely reported Proud study shows just how effective pre-exposure prophylaxis (PrEP) can be at preventing HIV transmission. PrEP is, quite simply, a game-changer and represents a wake-up call for the government, NHS England and local authorities to make PrEP a key component in our strategy to defeat HIV.

Published
26 February 2015
From
The Guardian
Combining PrEP and ART could almost eliminate HIV infection, east African study finds

Giving both pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) to heterosexual couples where one partner has HIV (serodiscordant couples) can almost eliminate the chance of infection in the

Published
26 February 2015
By
Gus Cairns
PrEP use rising in San Francisco, but scaling up could further cut new infections

Use of Truvada (tenofovir/emtricitabine) pre-exposure prophylaxis, better known as PrEP, is increasing in San Francisco, but it is still only reaching about one-third of people who could benefit,

Published
25 February 2015
By
Liz Highleyman
CDC Statement on IPERGAY Trial of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention among Men Who Have Sex with Men

The US Centers for Disease Control (CDC) today welcomed the news of the successful findings of the PROUD and Ipergay studies but expressed caution on interpreting Ipergay's results. CDC's director of HIV/AIDS, Viral Hepatitis, STD & TB prevention said: "Since available data suggest that men in this study were taking PrEP an average of three to four days per week, CDC cautions that researchers do not yet know if this regimen will work among MSM who have sex less frequently and would therefore be taking PrEP less often." The CDC , he added, "continues to recommend only daily use of PrEP, as approved by the FDA." However he noted that "the IPERGAY findings combined with other recent research suggests that even with less than perfect daily adherence, PrEP may still offer substantial protection if taken consistently."

Published
25 February 2015
From
CDC (US)
HIV and LGTB NGOs and other concerned actors across Europe call for futher action on pre-exposure prophylaxis

The European AIDS Treatment Group (EATG), Europe’s network of HIV activists, and  AIDES, a leading French NGO in the fight against AIDS and viral hepatitis, backed by 81 European HIV LGBT civil society organisations and concerned actors, issued an urgent HIV Prevention Manifesto today. We demand that pre-exposure prophylaxis for HIV (PrEP) is made available as soon as possible within the European Union, and that Gilead, the company that makes the PrEP medicine Truvada®, submits an application to the European Medicines Agency (EMA) for a change of indication so that its use to prevent HIV can be approved.

Published
25 February 2015
From
EATG
← First12345...51Next →

Filter by country